TY - JOUR
T1 - Lung cancer-specific symptoms and fear of cancer recurrence among recurrence-free non-small cell lung cancer survivors
AU - Lee, Genehee
AU - Ahn, Alice
AU - Lee, Dongok
AU - Kim, Tae Eun
AU - Kong, Sunga
AU - Kang, Danbee
AU - Kim, Hong Kwan
AU - Shim, Young Mog
AU - Cho, Juhee
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.
PY - 2024/5
Y1 - 2024/5
N2 - Purpose: Lung cancer survivors have more psychosocial problems, including depression and anxiety disorder, than other cancer survivors. Lung cancer-specific symptoms, such as cough, dyspnea, or pain in chest, might increase FCR among survivors. We aimed to evaluate the association between lung cancer-specific symptoms and FCR among recurrence-free non-small cell lung cancer (NSCLC) survivors. Methods: This is a cross-sectional study. Recurrence-free NSCLC survivors were recruited from January to October 2020 at a tertiary hospital in Seoul, Korea. We measured FCR using the Korean version of FCRI-SF and categorized them into three groups: non-clinical FCR (nFCR, < 13), subclinical FCR (sFCR, 13 to 21), and clinical FCR (cFCR, ≥ 22). Lung cancer-specific symptoms were measured using the Korean version of EORTC QLQ-LC13 and EORTC QLQ-C30. Results: A total of 727 survivors were enrolled. One-third (30.8%) of survivors reported sFCR, and 19.7% had cFCR. In a multivariate analysis, survivors with severe pain in chest were 4.7 times (95% CI: 2.4–9.0) more likely to experience cFCR compared to those without it. Mild dyspnea (OR 1.7, 95% CI: 1.1–2.7) and mild dysphagia (OR 2.4, 95% CI: 1.3–4.4) were associated with cFCR. Survivors with sFCR (Coef. − 6.3, 95% CI: − 9.8, − 2.8) and cFCR (Coef. − 11.3, 95% CI: − 15.5, − 7.2) had poorer quality of life compared to survivors with nFCR. Conclusion: NSCLC survivors were experiencing lung cancer-specific symptoms even a few years after treatment, which were associated with cFCR, resulting in poor HRQoL. It is necessary to develop a lung cancer-specific symptom checklist and use it during even long-term surveillance.
AB - Purpose: Lung cancer survivors have more psychosocial problems, including depression and anxiety disorder, than other cancer survivors. Lung cancer-specific symptoms, such as cough, dyspnea, or pain in chest, might increase FCR among survivors. We aimed to evaluate the association between lung cancer-specific symptoms and FCR among recurrence-free non-small cell lung cancer (NSCLC) survivors. Methods: This is a cross-sectional study. Recurrence-free NSCLC survivors were recruited from January to October 2020 at a tertiary hospital in Seoul, Korea. We measured FCR using the Korean version of FCRI-SF and categorized them into three groups: non-clinical FCR (nFCR, < 13), subclinical FCR (sFCR, 13 to 21), and clinical FCR (cFCR, ≥ 22). Lung cancer-specific symptoms were measured using the Korean version of EORTC QLQ-LC13 and EORTC QLQ-C30. Results: A total of 727 survivors were enrolled. One-third (30.8%) of survivors reported sFCR, and 19.7% had cFCR. In a multivariate analysis, survivors with severe pain in chest were 4.7 times (95% CI: 2.4–9.0) more likely to experience cFCR compared to those without it. Mild dyspnea (OR 1.7, 95% CI: 1.1–2.7) and mild dysphagia (OR 2.4, 95% CI: 1.3–4.4) were associated with cFCR. Survivors with sFCR (Coef. − 6.3, 95% CI: − 9.8, − 2.8) and cFCR (Coef. − 11.3, 95% CI: − 15.5, − 7.2) had poorer quality of life compared to survivors with nFCR. Conclusion: NSCLC survivors were experiencing lung cancer-specific symptoms even a few years after treatment, which were associated with cFCR, resulting in poor HRQoL. It is necessary to develop a lung cancer-specific symptom checklist and use it during even long-term surveillance.
KW - Fear of cancer recurrence
KW - Lung cancer
KW - Lung cancer-specific symptoms
KW - Quality of life
KW - Survivors
UR - https://www.scopus.com/pages/publications/85191892233
U2 - 10.1007/s00520-024-08505-3
DO - 10.1007/s00520-024-08505-3
M3 - Article
C2 - 38695959
AN - SCOPUS:85191892233
SN - 0941-4355
VL - 32
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 5
M1 - 322
ER -